Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
Journal Information
Full Title: J Hematol Oncol
Abbreviation: J Hematol Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe study was approved by the Medical Ethics Committee of the Union Hospital affiliated to Huazhong University of Science and Technology, Wuhan, China (REC ref no. [2019]009). All patients provided written informed consent. This study was registered on ClinicalTrials.gov, NCT04014894. Consent for publicationNot required. Competing interestsQi Chang and Cheng Liu are employed in Eureka Therapeutics, Inc, and the other authors declare no potential competing interests. Competing interests Qi Chang and Cheng Liu are employed in Eureka Therapeutics, Inc, and the other authors declare no potential competing interests."
"Funding This work was supported by grants from the National Key R&D Program of China (Nos. 2019YFC1316203 and 2019YFC1316204) and the National Natural Science Foundation of China (Nos. 81873434 and 82070124)."
"Trial registration : NCT04014894."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025